A Phase 4 interventional study of Secukinumab (AIN457) 150 mg s.c. and Secukinumab (AIN457) 150 mg s.c. in Ankylosing Spondylitis, sponsored by Novartis Pharmaceuticals. Completed at 39 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-08.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing secukinumab in Spondylitis, Ankylosing — 3 open to participants now, 4 under way, none of them phase 3. secukinumab · Spondylitis, Ankylosing.
Among the 20 studies testing secukinumab in Spondylitis, Ankylosing, this one is the 12th largest by enrollment, is one of 4 that started in 2016, is one of 6 in phase 4, and was the 10th registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
Browse Spondylitis, Ankylosing studies →3 of the 20 studies testing secukinumab in Spondylitis, Ankylosing are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Tongji Hospital · Sites in China
Ages 18–80
The Affiliated Hospital Of Guizhou Medical University · Sites in China
Ages 18+
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 211 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 223 across the 20 interventional studies. Of the 15 that completed or were terminated, 15 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
21 studies in Spondylitis, Ankylosing by Novartis: 2 open now, 2 under way, none of them phase 3. Of 19 finished, 17 (89%) have results posted.
Among the 21 studies in Spondylitis, Ankylosing by Novartis, this one is the 12th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2016, is one of 2 in phase 4, and was the 11th registered.
Novartis’s Spondylitis, Ankylosing studies by the year they started, since 2009.
1 of the studies testing secukinumab in Spondylitis, Ankylosing that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06833112The Affiliated Hospital Of Guizhou Medical UniversityInterleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing secukinumab in Spondylitis, Ankylosing, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 21 in Spondylitis, Ankylosing:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study assessed the clinical Assessment of SpondyloArthritis international Society (ASAS) 20 response to secukinumab and evaluated to which extent concomitant nonsteroidal anti-inflammatory drug (NSAID) treatment can be reduced in patients treated with secukinumab or placebo following an initial run-in phase of stable NSAID therapy.
This was a phase IV, 20-week, randomized, double-blind, 3-arm, placebo-controlled, parallel-group, multicenter study to examine the clinical response of secukinumab treatment in patients with ankylosing spondylitis as measured by the Assessment of SpondyloArthritis international Society (ASAS) 20 response and the nonsteroidal anti-inflammatory drug (NSAID)-sparing effect. This study evaluated to which extent nonsteroidal anti-inflammatory drug (NSAID) treatment can be reduced between Week 4 and Week 12 in patients randomized to secukinumab 150 mg or placebo following an initial run-in phase of 4 weeks on stable NSAID therapy. Two NSAID tapering approaches were evaluated in this study:
Patients were randomized 1:1:1 to one of the following treatment groups:
The primary objective of the study was to demonstrate that the efficacy of secukinumab 150 mg subcutaneous (s.c.) injection (with NSAID tapering) is superior to placebo based on the proportion of patients achieving an ASAS20 response at Week 12. To show superiority, both secukinumab treatment arms were pooled and compared against placebo.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Induction with secukinumab 150 mg s.c. once per week (Week 0, 1, 2, 3 and 4) followed by maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 8, 12, 16 and 20), with intermittent placebo injections at Week 5, 6, 7, 17, 18 and 19 to maintain the blind. NSAID tapering allowed from Week 4 (delayed tapering).
Drug: Secukinumab (AIN457) 150 mg s.c.
Placebo at weeks 0, 1, 2, 3 to maintain the blind; followed by induction with secukinumab 150 mg s.c. once per week (Week 4, 5, 6, 7, 8) and maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 12, 16 and 20), with intermittent placebo injections at Week 17, 18 and 19 to maintain the blind. NSAID tapering allowed from Week 4 (early tapering).
Drug: Secukinumab (AIN457) 150 mg s.c.
Placebo s.c. at Week 0, 1, 2, 3, 4, 5, 6, 7, 8 and 12. After the Week 16 assessments of the secondary endpoint had been performed, these patients received weekly doses of secukinumab 150 mg s.c. (Week 16, 17, 18, 19 and 20). NSAID tapering allowed from Week 4.
Drug: Placebo - Secukinumab (AIN457) 150 mg s.c.
Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 4 x 150 mg secukinumab s.c. every 4 weeks Delayed NSAID tapering (tapering following 4 weeks of secukinumab treatment).
Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 3 x 150 mg secukinumab s.c. every 4 weeks Early NSAID tapering (tapering at the start of secukinumab treatment).
Placebo for 15 weeks. From Week 16 on, 5 x 150 mg secukinumab s.c. weekly.
Proportion of Patients Who Achieved ASAS20 Response in the Pooled Secukinumab Group Compared With the Placebo Group at Week 12
ASAS (Assessment of SpondyloArthritis International Society criteria) 20 response is defined as an improvement from baseline of ≥20% and ≥1 unit on a scale of 0-10 in at least three of the four ASAS main domains and no worsening of ≥20% and ≥1 unit on a scale of 0-10 in the remaining domain. The four main ASAS domains are: Patient's global assessment of disease activity, back pain, function represented by ability to perform specific tasks (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]) and inflammation represented by mean duration and severity of morning stiffness. Non-responder imputation was applied for missing data.
Time frame: Baseline, Week 12
Proportion of Patients Who Achieved ASAS20 Response in Each Secukinumab Group (Delayed NSAID Tapering and Early NSAID Tapering) Compared With the Placebo Group
ASAS (Assessment of SpondyloArthritis International Society criteria) 20 response is defined as an improvement from baseline of ≥20% and ≥1 unit on a scale of 0-10 in at least three of the four ASAS main domains and no worsening of ≥20% and ≥1 unit on a scale of 0-10 in the remaining domain. The four main ASAS domains are: Patient's global assessment of disease activity, back pain, function represented by ability to perform specific tasks (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]) and inflammation represented by mean duration and severity of morning stiffness. Non-responder imputation was applied for missing data.
Time frame: Baseline, Week 12, Week 16
Mean Change From Baseline in ASAS-NSAID Score at Week 12
ASAS-NSAID score is used to present the NSAID (nonsteroidal anti-inflammatory drug) intake by considering the type of NSAID, the total dose and the number of days taking NSAID during a period of interest (PI). For the NSAID equivalence scoring system, "no NSAID intake" was set to a score value of 0, and the reference dose of 150 mg/day diclofenac was set to a score value of 100. The Daily diclofenac-equivalent dose score was derived by converting each daily dose of NSAID to a percentage dose equivalent of 150 mg diclofenac. ASAS-NSAID score = (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days). A negative change from baseline indicates less NSAID consumption.
Time frame: Baseline, Week 12
Mean Change From Baseline in ASAS-NSAID Score in Each Secukinumab Group After 12 Weeks of Exposure (at Week 12 in the Secukinumab-delayed NSAID Tapering Group and at Week 16 in the Secukinumab-early NSAID Tapering Group)
ASAS-NSAID score is used to present the NSAID (nonsteroidal anti-inflammatory drug) intake by considering the type of NSAID, the total dose and the number of days taking NSAID during a period of interest (PI). For the NSAID equivalence scoring system, "no NSAID intake" was set to a score value of 0, and the reference dose of 150 mg/day diclofenac was set to a score value of 100. The Daily diclofenac-equivalent dose score was derived by converting each daily dose of NSAID to a percentage dose equivalent of 150 mg diclofenac. ASAS-NSAID score = (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days). A negative change from baseline indicates less NSAID consumption. For this endpoint the analysis was performed after 12 weeks of exposure to secukinumab which was achieved at Week 12 in the secukinumab delayed NSAID tapering group but at Week 16 in the secukinumab early NSAID tapering group.
Time frame: Baseline, Week 12 (delayed NSAID tapering), Week 16 (early NSAID tapering)
Mean Change From Baseline in the BASDAI Total Score
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to ankylosing spondylitis: 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (captured as a continuous visual analog scale). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe symptoms. A negative change from baseline in the total 0-10 BASDAI score indicates improvement.
Time frame: Baseline, Week 12, Week 16
Mean Change From Baseline in Health-related Quality of Life as Measured by the Short Form-36 Health Survey (SF-36) Physical Component Summary (PCS) Score
The Short Form-36 Health Survey (SF-36) measures the impact of disease on overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36 (SF-36 PCS) that is evaluated in this study. Scores on each item 1-4 were summed and averaged (range = 0-100 with higher scores indicating better levels of function and/or better health). A positive change from Baseline indicates improvement.
Time frame: Baseline, Week 12
Participants took part in 40 investigative sites in Germany.
| Milestone | Secukinumab - Delayed NSAID Tapering | Secukinumab - Early NSAID Tapering | Placebo |
|---|---|---|---|
| Started | 71 | 70 | 70 |
| Completed | 62 | 65 | 62 |
| Not completed | 9 | 5 | 8 |
| Withdrew: Adverse event | 5 | 4 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 3 |
| Withdrew: Physician decision | 1 | 0 | 1 |
| Withdrew: Subject/guardian decision | 2 | 0 | 4 |
ASAS (Assessment of SpondyloArthritis International Society criteria) 20 response is defined as an improvement from baseline of ≥20% and ≥1 unit on a scale of 0-10 in at least three of the four ASAS main domains and no worsening of ≥20% and ≥1 unit on a scale of 0-10 in the remaining domain. The four main ASAS domains are: Patient's global assessment of disease activity, back pain, function represented by ability to perform specific tasks (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]) and inflammation represented by mean duration and severity of morning stiffness. Non-responder imputation was applied for missing data.
| Participants | Secukinumab - Pooled | Placebo |
|---|---|---|
| Proportion of Patients Who Achieved ASAS20 Response in the Pooled Secukinumab Group Compared With the Placebo Group at Week 12 | 72 | 31 |
ASAS (Assessment of SpondyloArthritis International Society criteria) 20 response is defined as an improvement from baseline of ≥20% and ≥1 unit on a scale of 0-10 in at least three of the four ASAS main domains and no worsening of ≥20% and ≥1 unit on a scale of 0-10 in the remaining domain. The four main ASAS domains are: Patient's global assessment of disease activity, back pain, function represented by ability to perform specific tasks (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]) and inflammation represented by mean duration and severity of morning stiffness. Non-responder imputation was applied for missing data.
| Participants | Secukinumab - Delayed NSAID Tapering | Secukinumab - Early NSAID Tapering | Placebo |
|---|---|---|---|
| Week 12 | 37 | 35 | 31 |
| Week 16 | 40 | 35 | 29 |
ASAS-NSAID score is used to present the NSAID (nonsteroidal anti-inflammatory drug) intake by considering the type of NSAID, the total dose and the number of days taking NSAID during a period of interest (PI). For the NSAID equivalence scoring system, "no NSAID intake" was set to a score value of 0, and the reference dose of 150 mg/day diclofenac was set to a score value of 100. The Daily diclofenac-equivalent dose score was derived by converting each daily dose of NSAID to a percentage dose equivalent of 150 mg diclofenac. ASAS-NSAID score = (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days). A negative change from baseline indicates less NSAID consumption.
| Score on scale | Secukinumab - Delayed NSAID Tapering | Secukinumab - Early NSAID Tapering | Placebo | Secukinumab - Pooled |
|---|---|---|---|---|
| Mean Change From Baseline in ASAS-NSAID Score at Week 12 | -44.9 ± 47.32 | -40.3 ± 71.48 | -31.5 ± 36.54 | -42.6 ± 60.53 |
ASAS-NSAID score is used to present the NSAID (nonsteroidal anti-inflammatory drug) intake by considering the type of NSAID, the total dose and the number of days taking NSAID during a period of interest (PI). For the NSAID equivalence scoring system, "no NSAID intake" was set to a score value of 0, and the reference dose of 150 mg/day diclofenac was set to a score value of 100. The Daily diclofenac-equivalent dose score was derived by converting each daily dose of NSAID to a percentage dose equivalent of 150 mg diclofenac. ASAS-NSAID score = (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days). A negative change from baseline indicates less NSAID consumption. For this endpoint the analysis was performed after 12 weeks of exposure to secukinumab which was achieved at Week 12 in the secukinumab delayed NSAID tapering group but at Week 16 in the secukinumab early NSAID tapering group.
| Score on scale | Secukinumab - Delayed NSAID Tapering | Secukinumab - Early NSAID Tapering |
|---|---|---|
| Mean Change From Baseline in ASAS-NSAID Score in Each Secukinumab Group After 12 Weeks of Exposure (at Week 12 in the Secukinumab-delayed NSAID Tapering Group and at Week 16 in the Secukinumab-early NSAID Tapering Group) | -44.9 ± 47.32 | -42.5 ± 68.62 |
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to ankylosing spondylitis: 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (captured as a continuous visual analog scale). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe symptoms. A negative change from baseline in the total 0-10 BASDAI score indicates improvement.
| Score on scale | Secukinumab - Delayed NSAID Tapering | Secukinumab - Early NSAID Tapering | Placebo | Secukinumab - Pooled |
|---|---|---|---|---|
| Week 12 | -2.1 ± 2.16 | -2.0 ± 2.10 | -1.8 ± 2.00 | -2.1 ± 2.12 |
| Week 16 | -2.3 ± 1.90 | -2.0 ± 1.96 | -1.7 ± 1.96 | -2.2 ± 1.93 |
The Short Form-36 Health Survey (SF-36) measures the impact of disease on overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36 (SF-36 PCS) that is evaluated in this study. Scores on each item 1-4 were summed and averaged (range = 0-100 with higher scores indicating better levels of function and/or better health). A positive change from Baseline indicates improvement.
| Score on scale | Secukinumab - Delayed NSAID Tapering | Secukinumab - Early NSAID Tapering | Placebo | Secukinumab - Pooled |
|---|---|---|---|---|
| Mean Change From Baseline in Health-related Quality of Life as Measured by the Short Form-36 Health Survey (SF-36) Physical Component Summary (PCS) Score | 4.8 ± 7.03 | 6.1 ± 6.92 | 4.8 ± 7.43 | 5.5 ± 6.98 |
Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 4 weeks post-treatment (median duration of 24 weeks).. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secukinumab - Delayed NSAID Tapering - Treatment Period 1 | 0/71 (0%) | 4/71 (5.6%) | 53/71 (74.6%) |
| Secukinumab - Early NSAID Tapering - Treatment Period 1 | 0/70 (0%) | 3/70 (4.3%) | 56/70 (80%) |
| Placebo - Treatment Period 1 | 0/70 (0%) | 1/70 (1.4%) | 55/70 (78.6%) |
| Secukinumab - Delayed NSAID Tapering - Treatment Period 2 | 0/71 (0%) | 1/71 (1.4%) | 25/71 (35.2%) |
| Secukinumab - Early NSAID Tapering - Treatment Period 2 | 0/70 (0%) | 0/70 (0%) | 23/70 (32.9%) |
| Placebo - Treatment Period 2 | 0/70 (0%) | 1/70 (1.4%) | 22/70 (31.4%) |
| Event | Secukinumab - Delayed NSAID Tapering - Treatment Period 1 | Secukinumab - Early NSAID Tapering - Treatment Period 1 | Placebo - Treatment Period 1 | Secukinumab - Delayed NSAID Tapering - Treatment Period 2 | Secukinumab - Early NSAID Tapering - Treatment Period 2 | Placebo - Treatment Period 2 |
|---|---|---|---|---|---|---|
| IridocyclitisEye disorders | 0/71 | 0/70 | 0/70 | 0/71 | 0/70 | 1/70 |
| Abdominal herniaGastrointestinal disorders | 0/71 | 1/70 | 0/70 | 0/71 | 0/70 | 0/70 |
| Abdominal painGastrointestinal disorders | 0/71 | 1/70 | 0/70 | 0/71 | 0/70 | 0/70 |
| Inguinal herniaGastrointestinal disorders | 0/71 | 1/70 | 0/70 | 0/71 | 0/70 | 0/70 |
| ErysipelasInfections and infestations | 0/71 | 0/70 | 1/70 | 0/71 | 0/70 | 0/70 |
| ColitisGastrointestinal disorders | 1/71 | 0/70 | 0/70 | 0/71 | 0/70 | 0/70 |
| Crohn's diseaseGastrointestinal disorders | 1/71 | 0/70 | 0/70 | 0/71 | 0/70 | 0/70 |
| GastritisGastrointestinal disorders | 1/71 | 0/70 | 0/70 | 0/71 | 0/70 | 0/70 |
| Oesophageal ulcerGastrointestinal disorders | 1/71 | 0/70 | 0/70 | 0/71 | 0/70 | 0/70 |
| NephrolithiasisRenal and urinary disorders | 1/71 | 0/70 | 0/70 | 0/71 | 0/70 | 0/70 |
| Event | Secukinumab - Delayed NSAID Tapering - Treatment Period 1 | Secukinumab - Early NSAID Tapering - Treatment Period 1 | Placebo - Treatment Period 1 | Secukinumab - Delayed NSAID Tapering - Treatment Period 2 | Secukinumab - Early NSAID Tapering - Treatment Period 2 | Placebo - Treatment Period 2 |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 6/71 | 13/70 | 14/70 | 7/71 | 5/70 | 3/70 |
| HeadacheNervous system disorders | 12/71 | 10/70 | 6/70 | 4/71 | 3/70 | 1/70 |
| Ankylosing spondylitisMusculoskeletal and connective tissue disorders | 3/71 | 1/70 | 6/70 | 2/71 | 0/70 | 1/70 |
| NauseaGastrointestinal disorders | 2/71 | 2/70 | 5/70 | 0/71 | 0/70 | 1/70 |
| BronchitisInfections and infestations | 5/71 | 2/70 | 3/70 | 2/71 | 1/70 | 1/70 |
| GastroenteritisInfections and infestations | 2/71 | 4/70 | 3/70 | 1/71 | 0/70 | 1/70 |
| Respiratory tract infectionInfections and infestations | 2/71 | 4/70 | 3/70 | 1/71 | 1/70 | 3/70 |
| HypertensionVascular disorders | 4/71 | 3/70 | 4/70 | 0/71 | 0/70 | 1/70 |
| RhinitisInfections and infestations | 4/71 | 0/70 | 2/70 | 0/71 | 0/70 | 0/70 |
| Back painMusculoskeletal and connective tissue disorders | 4/71 | 1/70 | 1/70 | 0/71 | 0/70 | 0/70 |
| Age, Continuous(Years) | Secukinumab - Delayed NSAID Tapering | Secukinumab - Early NSAID Tapering | Placebo | Total |
|---|---|---|---|---|
| Mean | 46.2 ± 13.36 | 44.1 ± 11.02 | 45.4 ± 12.55 | 45.2 ± 12.32 |
| Sex: Female, Male(Participants) | Secukinumab - Delayed NSAID Tapering | Secukinumab - Early NSAID Tapering | Placebo | Total |
|---|---|---|---|---|
| Female | 30 | 28 | 31 | 89 |
| Male | 41 | 42 | 39 | 122 |
| Race/Ethnicity, Customized(Participants) | Secukinumab - Delayed NSAID Tapering | Secukinumab - Early NSAID Tapering | Placebo | Total |
|---|---|---|---|---|
| Caucasian | 69 | 67 | 68 | 204 |
| Black | 1 | 0 | 0 | 1 |
| Asian | 0 | 2 | 1 | 3 |
| Other | 1 | 1 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from May 2016 to primary completion in Sep 2019, 39 months.
Results were first posted in Oct 2020, 1 year after primary completion.
Of 18 phase 4 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 36. This study's 39 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab